Delivery Order SPE2DB22D3501-SPE2DB25FWG84
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,018.51 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with a completion date of June 3, 2025. The pharmaceutical products will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,191.11 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. The contract was competitively awarded with no set-aside designation and carries a firm fixed price structure, with an ultimate completion date of August 18, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and primary pharmaceutical distributor for this federal...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $39,010.77 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. The contract is a firm fixed price delivery order with an ultimate completion date of September 22, 2025, and was competitively awarded without set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal...
- The Defense Logistics Agency (DLA) awarded a $26,261.81 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,141.13 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 28, 2025. The contract was awarded on August 27, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,084.96 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. The contract is a firm fixed-price delivery order with an ultimate completion date of June 3, 2025, and was competitively awarded without set-aside provisions. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical procurement supporting federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,386.62 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This competitively awarded, firm fixed-price delivery order is scheduled for completion by April 30, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was awarded through open competition to the most...
- The Defense Logistics Agency awarded a $34,710.25 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3ml vials under a firm fixed-price contract. The award, issued on July 18, 2025, with an ultimate completion date of July 21, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement needs, particularly...
- The Defense Logistics Agency awarded a $8,586.16 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with completion targeted for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is performed out of the contractor's Conshohocken, Pennsylvania location. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,523.67 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This firm fixed-price, competitively awarded contract (no set-aside used) is effective through August 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical delivery under the company's existing federal contract framework...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWG84Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,595.00 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This non-set-aside, competitively awarded contract employs firm fixed pricing and is scheduled for completion by July 7, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA's Medical Supply Chain. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a total value of $999,999,999.00 and extends through December 2026. The IDC functions as a comprehensive global pharmaceutical support vehicle, enabling the contractor to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. The contract award reflects the DLA's ongoing strategy to maintain reliable pharmaceutical supply chains for defense health operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 7/3/25 |